Literature DB >> 5038327

Further observations on the effect of C. parvum and anti-tumour globulin on syngeneically transplanted mouse tumours.

M F Woodruff, M P Inchley, N Dunbar.   

Abstract

The inhibitory effect of an i.v. or i.p. injection of C. parvum on intrastrain transplants of a mammary carcinoma in A/HeJ mice has been confirmed, and it has been shown further that C. parvum inhibits the growth of transplants of sarcomata induced with methylcholanthrene both in this strain (members of which lack the fifth component of complement) and in CBA mice (which are not complement deficient). In experiments with the mammary carcinoma, 2 injections of C. parvum on days + 3 and + 9 were more effective than a single injection on day + 3; injections on days + 3 and + 6, or + 3 and + 12, appeared to be marginally less effective than on days + 3 and + 9, but the difference was not statistically significant.Development of the CBA sarcoma was inhibited to about the same extent if, instead of treating the mouse with C. parvum, the tumour cells were pre-incubated with anti-tumour globulin (ATG) in the absence of complement prior to inoculation, and the effect of combining these procedures was much greater than that of either alone. Pre-incubation with ATG had a similar but less marked effect on the development of the mammary carcinoma but had no effect on the A/HeJ sarcoma. Injection (i.v.) of ATG did not inhibit the growth of any of the tumours in these experiments and possible reasons for this are discussed.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5038327      PMCID: PMC2008436          DOI: 10.1038/bjc.1972.11

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Immunological treatment of leukaemias.

Authors:  G Mathé
Journal:  Br Med J       Date:  1970-11-21

2.  Cytolytic efficiency of rabbit-anti-mouse antilymphocytic globulin and its augmentation by antiglobulin.

Authors:  M F Woodruff; M P Inchley
Journal:  Clin Exp Immunol       Date:  1971-12       Impact factor: 4.330

3.  Comparative effect of two strains of C. parvum on phagocytic activity and tumour growth.

Authors:  L H Smith; M F Woodruff
Journal:  Nature       Date:  1968-07-13       Impact factor: 49.962

4.  Cytotoxic efficiency and effect on tumour growth of heterospecific antilymphocytic and antitumour sera.

Authors:  M Woodruff; L H Smith
Journal:  Nature       Date:  1970-01-24       Impact factor: 49.962

5.  Remission induction with Poly IC in patients with acute lymphoblastic leukaemia (preliminary results).

Authors:  G Mathé; J L Amiel; L Schwarzenberg; M Schneider; M Hayat; F de Vassal; C Jasmin; C Rosenfeld; M Sakouhi; J Choay
Journal:  Rev Eur Etud Clin Biol       Date:  1970 Jun-Jul

6.  [Demonstration of the efficacy of active immunotherapy in human acute lymphoblastic leukemia].

Authors:  G Mathé; J L Amiel; L Schwarzenberg; M Schneider; A Cattan; J R Schlumberger; M Hayat; F de Vassal
Journal:  Rev Fr Etud Clin Biol       Date:  1968-05

Review 7.  Passive immunotherapy of leukemia and other cancer.

Authors:  R Motta
Journal:  Adv Cancer Res       Date:  1971       Impact factor: 6.242

8.  Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcomas.

Authors:  G A Currie
Journal:  Br Med J       Date:  1970-02-28

9.  Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts.

Authors:  M F Woodruff; J L Boak
Journal:  Br J Cancer       Date:  1966-06       Impact factor: 7.640

10.  Synergistic inhibition of mammary carcinoma transplants in A-strain mice by antitumour globulin and C. parvum.

Authors:  M F Woodruff; M P Inchley
Journal:  Br J Cancer       Date:  1971-09       Impact factor: 7.640

View more
  11 in total

Review 1.  Suppression of the immune response by microorganisms.

Authors:  J H Schwab
Journal:  Bacteriol Rev       Date:  1975-06

2.  The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer.

Authors:  J P Minton; J L Rossio; B Dixon; M C Dodd
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

3.  Characterization of mouse peritoneal exudate and associated leukocyte adherence inhibitory activity after intraperitoneal injection of either Bordetella pertussis or Corynebacterium parvum vaccines.

Authors:  T W Klein; S H Pross; W R Benjamin
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

4.  Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.

Authors:  M F Woodruff; W H McBride; N Dunbar
Journal:  Clin Exp Immunol       Date:  1974-07       Impact factor: 4.330

5.  Antibodies to tumour eluates react preferentially with non-lymphoid tumours.

Authors:  J E Boyd; K James
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Interactions of asbestos-activated macrophages with an experimental fibrosarcoma.

Authors:  K Donaldson; J M Davis; A Ewing; K James
Journal:  Environ Health Perspect       Date:  1983-09       Impact factor: 9.031

7.  Cimetidine and therapy of rodent tumours.

Authors:  D Hannant; K James; R E Bolton; M D Robertson; I Milne
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

8.  Immunological and biochemical characteristics of acid citrate eluates from tumour cells: a major non-immunoglobulin component.

Authors:  K James; S Davis; J Merriman
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

9.  Effect of C. Parvum on immunization with irradiated tumour cells.

Authors:  M F Woodruff; A Ghaffar; N Dunbar; V L Whitehead
Journal:  Br J Cancer       Date:  1976-05       Impact factor: 7.640

10.  Antitumour responses induced by short-term pretreatment with tumour cells.

Authors:  K James; R T Cullen; I Milne; M Norval
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.